27 أبريل #aimless #Chemotherapy #last month Treatment of cancer patients in their last month of life: aimless chemotherapy by Dr. Fadi Farhat 0
12 ديسمبر #Lebanon A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon by Dr. Fadi Farhat 0
20 أغسطس #attitude #Cancer #cross-sectional study #family #friend #nurse #physician Revealing a cancer diagnosis to patients: attitudes of patients, families, friends, nurses, and physicians in Lebanon-results of a cross-sectional study by Dr. Fadi Farhat 0
10 أغسطس #advanced #cisplatin #first-line therapy #maintenance #non-small cell lung cancer #Oral #vinorelbine Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer by Dr. Fadi Farhat 0
04 يناير #Chemotherapy #Hypertension #immunosuppression #new challenge Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge by Dr. Fadi Farhat 0
25 نوفمبر #Adenocarcinoma #Epidermal #growth factor #KRAS #Lebanese #Lung #Mutations #population #receptor #retrospective #study Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population by Dr. Fadi Farhat 0
25 مايو #anti-angiogenic #Cutaneous #focus #inhibitors #manifestation #oncology #review #therapy #VEGF Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors by Dr. Fadi Farhat 0
11 أكتوبر #Lebanon #lymphoma #nationwide #virus A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses. by Dr. Fadi Farhat 0
17 يوليو #non-small cell lung cancer #NSCLC #targeted #therapy Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? by Dr. Fadi Farhat 0
17 يناير #calcitriol #castration-resistant prostate cancer #Docetaxel #High-dose #Phase II #study #zolandronic acid High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study by Dr. Fadi Farhat 0
